Diastolic Heart Failure
Conditions
Keywords
Diastolic Heart Failure, Hispanic Americans, Aliskiren, Spironolactone, Lisinopril, Diastolic Heart Failure in Hispanic Americans
Brief summary
This study is being conducted to compare the effects that 2 different combinations of heart failure medications have on the levels of certain blood markers which cause and/or worsen heart failure. Additionally, the investigators will investigate any differences that may exist between Hispanics and Non-Hispanics. The investigators hope to find that Hispanic Americans will have a greater response to this new regimen compared to non-Hispanic Americans.
Detailed description
Our main hypothesis is that in contrast to non Hispanic whites, the degree of RAAS system activation is more pronounced in Mexican Americans with diastolic HF and consequently their response to RAAS inhibition therapy is greater. Blocking the RAAS with renin inhibitor plus aldosterone receptor blocker should produce measurable changes in biomarkers as well as physiologic improvement that could therefore translate into improved clinical outcomes. These changes should be greater appreciated in Mexican Americans if the central pathophysiologic influence of HF in this population was RAAS maladaptation.
Interventions
DRUGAliskiren plus spironolactone vs. Lisinopril plus spironolactone
Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
Sponsors
Texas Tech University Health Sciences Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Chronic stable diastolic HF documented by clinical diagnosis and echocardiogram within the last 2 years 2. NYHA classes I-III, symptomatically stable (for \>1month) 3. Age 21-70 years 4. Either of Hispanic ethnicity (Mexican American origin) or non-Hispanic white 5. Patients on ACE inhibitor therapy (lisinopril) 6. Blood pressure \>100/75 mmHg 7. Adequate birth control 8. Patients seen in TTUHSC Cardiology or Internal Medicine clinic for at least two visits since January 2008
Exclusion criteria
1. Acute coronary syndrome (within the last month). 2. Recent acute diastolic or systolic HF (within the last month) 3. Pancreatic disease 4. Renal artery stenosis 5. Pregnancy 6. History of angioedema 7. Severe hypotension (systolic BP\<90mmHg or mean arterial pressure \<65mmHg) 8. Hyperkalemia (defined by K+\>5 mEq/L) 9. Chronic Kidney Disease (Stage 3 and above) 10. Systolic dysfunction (ejection fraction below 50%) 11. Ethnicity other than Mexican American or non-Hispanic white
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare the baseline level of RAAS dysregulation between Mexican Americans and non-Hispanic whites with stable diastolic HF by measuring established biomarkers. | 8 weeks |
| Evaluate the superiority of aliskiren plus spironolactone combination over an lisinopril plus spironolactone combination in inhibiting the RAAS system among patients with diastolic HF. | 8 weeks |
| Compare the clinical and biological benefit of RAAS system inhibition between aliskiren plus spironolactone and lisinopril plus spironolactone as measured by clinical indicators and serum biomarkers | 8 weeks |
| Assess ethnicity-specific differences in the clinical response to either RAAS inhibition treatment between Mexican Americans and non-Hispanic whites. | 8 weeks |
Countries
United States
Outcome results
None listed